Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Procedure guideline for radionuclide cystography in children.

BIBLIOGRAPHIC SOURCE(S)

  • Mandell GA, Eggli DF, Gilday DL, Heyman S, Leonard JC, Miller JH, Nadel HR, Piepsz A, Treves ST. Procedure guideline for radionuclide cystography in children, 3.0. Reston (VA): Society of Nuclear Medicine; 2003 Jan 25. 6 p. [7 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Society of Nuclear Medicine. Procedure guideline for radionuclide cystography in children, 2.0. Reston (VA): Society of Nuclear Medicine; 1999 Feb. 18 p. (Society of Nuclear Medicine procedure guidelines; no. 2.0).

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Background Information and Definitions

Urinary tract infection is a common problem in the pediatric population. The signs and symptoms are nonspecific, particularly in the younger child. The role of vesicoureteral reflux in the pathogenesis of pyelonephritis is incompletely understood. Approximately 40% of patients with upper urinary tract infection have vesicoureteral reflux. Urinary tract infection, unrecognized and inadequately treated, can lead to hypertension and chronic renal failure.

  1. Radionuclide cystography (RNC) is a method to evaluate for vesicoureteral reflux, which results in significantly less gonadal radiation when compared with conventional radiographic technique (voiding cystourethrogram [VCUG]). In addition, radionuclide cystography has a sensitivity for detection of vesicoureteral reflux equal to that of VCUG. Radionuclide cystography does not provide the same anatomic detail as a VCUG.
  2. Direct radionuclide cystography (DRC) requires catheterization of the bladder and instillation of radionuclide and fluid for maximum distension of the bladder, allowing imaging during filling, voiding and after voiding.
  3. Indirect radionuclide cystography (IRC) does not require bladder catheterization but does require the intravenous injection of the radiopharmaceutical for evaluation of renal function, urine drainage, and detection of vesicoureteral reflux.

Common Indications

  1. Initial evaluation of females with urinary tract infection for reflux
  2. Diagnosis of familial reflux
  3. Evaluation of vesicoureteral reflux after medical management
  4. Assessment of the results of antireflux surgery
  5. Serial evaluation of bladder dysfunction (e.g. neurogenic bladder) for reflux

Procedure

The detailed procedure recommendations in the guideline address the following areas: patient preparation; information pertinent to performing the procedure (i.e., important data that the physician should have about the patient at the time the exam is performed and interpreted); precautions; information regarding the radiopharmaceutical (i.e., ranges of administered activity, organ receiving the largest radiation dose, effective dose), image acquisition; interventions; processing; interpretation/reporting; quality control, and sources of error.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting the recommendations is not specifically stated.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Mandell GA, Eggli DF, Gilday DL, Heyman S, Leonard JC, Miller JH, Nadel HR, Piepsz A, Treves ST. Procedure guideline for radionuclide cystography in children, 3.0. Reston (VA): Society of Nuclear Medicine; 2003 Jan 25. 6 p. [7 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Feb (revised 2003 Jan 25)

GUIDELINE DEVELOPER(S)

Society of Nuclear Medicine, Inc - Medical Specialty Society

SOURCE(S) OF FUNDING

Society of Nuclear Medicine (SNM)

GUIDELINE COMMITTEE

Task Force

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Authors: Gerald A. Mandell, MD (DuPont Hospital for Children, Wilmington, DE); Douglas F. Eggli, MD (Pennsylvania State University/Milton S. Hershey Medical Center, Hershey, PA); David L. Gilday, MD (Hospital for Sick Children, Toronto, Ontario, Canada); Sydney Heyman, MD (Children's Hospital of Philadelphia, Philadelphia, PA); Joe C. Leonard, MD (Oklahoma Children's Memorial Hospital, Oklahoma City, OK); John H. Miller, MD (Children's Hospital Los Angeles, Los Angeles, CA); Helen R. Nadel, MD (Children's Hospital, British Columbia, Vancouver, Canada); Amy Piepsz, MD (CHU St. Pierre, Department of Radioisotopes, Brussels, Belgium); and S. Ted Treves, MD (Children's Hospital, Boston, MA)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Society of Nuclear Medicine. Procedure guideline for radionuclide cystography in children, 2.0. Reston (VA): Society of Nuclear Medicine; 1999 Feb. 18 p. (Society of Nuclear Medicine procedure guidelines; no. 2.0).

GUIDELINE AVAILABILITY

Electronic copies of the updated guideline: Available from the Society of Nuclear Medicine (SNM) Web site.

Print copies: Available from SNM, Division of Health Care Policy, 1850 Samuel Morse Dr, Reston, VA 20190-5316; Phone: 1-800-513-6853 or 1-703-326-1186; Fax: 703-708-9015; E-Mail: ServiceCenter@snm.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Print copies: Available from SNM, Division of Health Care Policy, 1850 Samuel Morse Dr, Reston, VA 20190-5316; Phone: 1-800-513-6853 or 1-703-326-1186; Fax: 703-708-9015; E-Mail: ServiceCenter@snm.org.

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on July 20, 1999. It was verified by the guideline developer as of August 5, 1999. This NGC summary was updated by ECRI on April 14, 2005.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo